Menin抑制剂治疗失败后复发或难治性急性髓系白血病的结局
这项多中心回顾性研究分析了84例Menin抑制剂治疗失败的复发/难治性急性髓系白血病成人患者,其中63%为KMT2A重排、23%为NPM1突变。
要点
- Menin抑制剂失败后预后差,中位总生存仅4.4个月。
- 失败后接受治疗者CR/CRi率19%,总体缓解率32%。
- CR/CRi仅见于含维奈克拉方案或Menin抑制剂互换。
核心结论
- Menin抑制剂治疗失败后的复发/难治性AML结局较差,但含维奈克拉方案或Menin抑制剂互换仍可能获得缓解。
- FLT3-ITD、WT1和MEN1突变与耐药相关。
研究设计与样本
- 多中心回顾性研究,纳入4个美国中心的成人复发/难治性AML患者,均为Menin抑制剂治疗失败(缓解后复发或原发难治)。
- 共84例接受Menin抑制剂治疗的患者,其中63%(n=53)为KMT2A重排,23%(n=19)为NPM1突变。
- 患者既往接受过大量治疗:86%(n=72)曾接受强化化疗,77%(n=67)曾接受维奈克拉。
主要发现
- Menin抑制剂失败后,40%(n=34)的患者仅接受支持治疗。
- 接受治疗的患者(n=50)常用方案包括去甲基化药物/维奈克拉(26%,n=13)、临床试验(26%,n=13)和基于吉瑞替尼的治疗(18%,n=9)。
- 非临床试验方案的CR/CRi率为19%(n=7),总体缓解率为32%(n=12)。
- 所有CR/CRi均发生于去甲基化药物/维奈克拉(n=2,15%)、强化化疗+维奈克拉(n=4,67%)或Menin抑制剂互换(bleximenib换为revumenib,n=1,50%)。
- 携带FLT3-ITD突变且未接受过吉瑞替尼的患者对吉瑞替尼均无缓解(0/6)。
临床怎么用
- Menin抑制剂失败后应积极评估患者是否适合含维奈克拉方案或Menin抑制剂互换等治疗。
- FLT3-ITD、WT1和MEN1突变可能提示耐药,需在治疗选择时加以考虑。
局限性
- 回顾性研究设计。
- 样本量较小(84例)。
- 仅纳入4个美国中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Menin inhibitors (MENINi) show promise for relapsed or refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2Ar) and nucleophosmin 1 mutations (NPM1c). Outcomes after MENINi failure are poorly understood. To characterize the mutational landscape and subsequent outcomes, we conducted a multicenter retrospective study of adults from 4 US centers with R/R AML after MENINi failure (relapse after response or primary refractory). The 84 patients (63% KMT2Ar, n = 53; 23% NPM1c, n = 19) who received MENINi were heavily pretreated: 86% (n = 72) had previous intensive chemotherapy (IC) and 77% venetoclax (VEN; n = 67). After MENINi failure, 40% of patients (n = 34) received supportive care. For the treated patients (n = 50), common regimens included hypomethylating agent (HMA)/VEN (26%, n = 13), clinical trial (26%, n = 13), and gilteritinib-based therapy (18%, n = 9). The complete response (CR)/CR with incomplete hematologic recovery (CRi) rate for nontrial therapies was 19% (n = 7); overall response rate was 32% (n = 12). All CR/CRi occurred with HMA/VEN (n = 2, 15%), IC + VEN (n = 4, 67%), or MENINi switching (bleximenib to revumenib, n = 1 [50%]). No patient with FLT3-ITD mutation responded to gilteritinib (0/6 gilteritinib-naïve). Median overall survival from start of next therapy was 4.4 months and superior for patients who achieved CR/CRi, (15.4 vs 3.4 months, P = .048). Outcomes after MENINi failure are poor, but responses occur with VEN-based regimens or MENINi switching. FLT3-ITD, WT1, and MEN1 mutations are associated with resistance.
引用
- Chin KK, Ball BJ, Abaza Y, et al. Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. Blood Adv. 2026. PMID: 41351513. doi:10.1182/bloodadvances.2025018178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。